BillionToOne, Inc. (BLLN) Earnings Call Transcript
November 4, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thank you for being part of today's conference call. On the line with me from BillionToOne are Ozan Atay, our Co-Founder and Chief Executive Officer, and Ross Taylor, our Chief Financial Officer. BillionToOne issued its financial results earlier today for the third quarter, which ended September 30th, 2026. You can find a copy of the press release on the company's website. Before we get started, I'd like to remind you that we may make forward-looking statements during this call within the meaning of federal securities laws. Statements of that kind about future events may cover our financial outlook and performance, market size, our products and services, reimbursement coverage, future clinical performance, and other similar matters. We want to flag that these remarks represent our best assessment as of right now, and what actually happens could vary significantly from what any forward-looking statements say or suggest. The risk factors that might lead to different outcomes are covered in the documents we file with the SEC — among them the annual report on Form 10-K we filed earlier, the quarterly report on Form 10-Q that will be submitted after this call, and the current report on Form 8-K filed today. Every forward-looking statement in this call speaks only as of today, November 4th, 2026. Should anyone replay or review this call after today, the information presented here might no longer be current or accurate. BillionToOne states it has no duty to revise any forward-looking statements publicly—whether due to fresh information, later events, or other reasons—unless the law demands it. On that note, I'll hand things over to Ozan.
Good afternoon, everyone, and thanks for joining our Q3 2026 earnings call. Before I get started, I want to acknowledge the people who make our work possible. To the patients and providers who depend on us at the most critical moments of their care, thank you for trusting us. To our employees: your dedication is what lets us produce superior tests that lead to better care and free our patients from the fear of the unknown. Before I move on to the quarter's results, let me remind you of the four pillars that guide our strategy and distinguish BillionToOne from other molecular diagnostics companies. Our first pillar is the foundation. Our proprietary quantitative counting template, or QCT, technology has enabled us to build category-defining products in prenatal and oncology, and those products fuel our second pillar: scalable rapid growth. In only six years we've expanded quickly to a $492 million annualized revenue run rate, and we feel we've barely begun to tap a $100 billion yearly cell-free DNA testing opportunity across prenatal and oncology within the US by itself. A superior gross margin profile is our third pillar; combined with unwavering discipline on both ASPs and COGS, it keeps our gross margin above 70% as of today, and we see further room for expansion over the long term. GAAP profitability stands as our fourth pillar. By pairing that margin framework with our habit of watching every dollar and running operations with AI, we achieved GAAP profitability and positive cash flow, all while our accumulated deficit sits at roughly one-tenth of the figure our public peers disclose. The long-term aim stays the same: we are building an enduring company—one that will redefine the molecular diagnostics standard of care for millions of patients. In Q3, we came through on each of our four pillars. We had another strong quarter, with revenue reaching a record level that showed fast expansion as well as GAAP profitability—a combination that remains very rare in molecular diagnostics—plus advances on products and clinical studies that can position us for exceptional growth and results in the coming years. Quickly reviewing each pillar: under the first, we released two important studies. First, the Green Journal, the leading publication for OB-GYNs, ran our paper on the first and only peer-reviewed prospective trial in single-gene NIPT. On the oncology side, the Journal of Liquid Biopsy published what we consider the first head-to-head comparison of a tissue-free test, Northstar Response, versus a tumor-informed assay for response monitoring, and the results were on par to superior. We're bringing Northstar Clear, our tissue-free MRD test, to market on December 15th, and I'll return to that in a moment. Turning to rapid growth, prenatal revenue rose 42% while oncology revenue climbed 96%, which brought total Q3 revenue growth to 47% year-over-year. Gross margins came in steady at 71% for the quarter, even though cost of goods sold per test climbed 10% to $169 as oncology grew faster. To close, GAAP operating income came in at $11 million, a 9% GAAP operating margin, while adjusted EBITDA margin hit 18% — pretty impressive. That marked our fifth quarter in a row with positive GAAP operating income. Cash flow was positive too, and we ended the quarter holding $562 million in cash; let me now go through each pillar in more detail. Starting with pillar one, our smMIPs platform and products. Clinical evidence is what elevates a solid platform into the standard of care, and during this quarter we substantially broadened that evidence base in both prenatal and oncology as we get ready for the next major product launch. Starting with prenatal: on August 18th, we came out with the first and largest prospective study of a single-gene non-invasive prenatal test, conducted in the population it is meant for, and it confirms the test as a first-line screen. The study appeared in the top journal for OB-GYNs, the Green Journal, and was done in partnership with nine US institutions. That is exactly the kind of high-quality evidence that can shift clinical practice. For more than 98% of the 2,212 pregnancies examined, we obtained outcomes. The UNITY Fetal Risk Screen demonstrated 94.4% sensitivity along with 99.5% specificity, and it held up consistently within a racially and ethnically diverse population in the US. For context, with traditional screening the maximum fetal risk a family can be given is 1 in 4. UNITY provides a personalized fetal risk ranging from as high as 9 in 10 down to as low as 1 in 10,000. Other studies have drawn most affected fetuses from couples already deemed high-risk; by contrast, this prospective multisite study was run in the intended-use general population, and outcome collection was nearly complete. As a result, it represents the strongest form of evidence demonstrating that the assay succeeds in identifying affected fetuses with high sensitivity and specificity. In our view, this publication establishes UNITY as the leading cell-free DNA screening option for recessive single-gene conditions. Now moving to oncology: we published something on October 7th in the Journal of Liquid Biopsy that we view as the first head-to-head comparison against the most commonly used tumor-informed assay in patients receiving active treatment for advanced cancer. This was a pan-cancer, real-world comparison, and the data came from providers who use both assays in clinical practice. The results show Northstar Response delivering outcomes that are equal to or better than the tumor-informed assay—and to our knowledge, this is the first instance of a tissue-free test demonstrating superior head-to-head performance versus a tumor-informed assay. In 94% of sequential pairs, the two tests indicated the same direction of ctDNA changes. In cases where the two approaches gave different answers, though, the patient's clinical records backed up what Northstar Response found. The tumor-informed assay, by contrast, generated false positives or false negatives relative to how the patient actually responded or progressed clinically. Because tumors evolve with time, this study demonstrates that a test constructed from tissue gathered years before can at times return inaccurate results. It also demonstrates that physicians need not sacrifice performance in order to gain the quicker turnaround and other logistical advantages a tissue-free test provides. This study vividly illustrates the precision of our QCT technology and strengthens the evidence behind Northstar Response. We anticipate that these data will speed up uptake of Response and make it even more certain that Medicare coverage for Response is a question of when, not if. We're pleased to share that Northstar Clear, our tissue-free MRD test, launches commercially on December 15th. Clear is a pan-cancer test requiring only a blood draw, and it's available for all solid tumors from day one—no waiting for a tissue sample or needing to build a patient-specific assay. What we aimed to achieve with Clear is tissue-free MRD that performs like a tumor-informed test. MRD represents roughly a $30 billion yearly opportunity, and we believe our tissue-free MRD assay is the most sensitive one on the market. When we launch, we'll show head-to-head results versus a tumor-informed competitor. That comparison will start with colorectal cancer, but the test will be offered for all solid tumor types. Through 2027 and after, we'll keep generating further evidence across every solid tumor. Clear also marks an important step in growing our platform. Alongside Select and Response, Clear means the Northstar portfolio now spans both early and late-stage care, with all of it built on the same QCT technology.
Our work on Clear additionally lays the groundwork for our bigger-picture chance in early detection. Fundamentally speaking, detecting residual disease without tissue and spotting cancer early pose fairly comparable technical problems, because each requires finding tumor DNA at extremely low concentrations in situations where no tissue specimen exists. Launching our MRD offering therefore substantially reduces the risk attached to our long-range ambitions for a highly sensitive early detection assay. Turning to our second pillar, scalable rapid growth: third-quarter total test volume climbed 25% versus a year earlier, reaching approximately 206,000 tests — over 10,000 more than the prior quarter — with quarter-over-quarter gains in prenatal as well as oncology. Three main factors fueled that robust testing volume: our teams executed well, we had more field sales representatives, and the product improvements we've rolled out in both prenatal and oncology kept getting a favorable response. On the prenatal side, we remain focused on expanding into bigger health systems, and that's still a substantial opportunity. Backing this up are our new 130-gene fetal risk screen, the category-defining UNITY confirm test, and Epic Aura integration; in oncology, volume growth was outstanding once more, powered by our growing sales team and ongoing uptake of our PGx, CH, and tissue-of-origin enhancements. Prenatal and oncology both contributed meaningfully to growth in the third quarter. Prenatal brought in $106 million, a 42% increase versus the prior year, equal to an annualized run rate of $424 million. Oncology revenue essentially doubled, rising 96% year-over-year to $17 million, an annualized run rate of roughly $68 million. The total revenue we delivered in the third quarter shows how well we have executed remarkable growth across the last six years. Starting from essentially zero, we have built a business with a $492 million annualized revenue run rate in about six years. Prenatal and oncology combined produced record total revenue of $123 million in the third quarter, up 47% year-over-year and 12% quarter-over-quarter. That expansion came from a 25% rise in test volume and an 18% rise in ASP. Now on to pillar three, our strong gross margin profile. Regarding ASPs for the quarter, overall ASP rose 7% quarter over quarter and 18% year over year, reaching $589 per test. Prenatal and oncology ASPs both went up quarter over quarter. Leaving out true-up revenue, overall ASP came to $552, up 3% sequentially and 15% year over year; this gain stemmed from additional payer contracts, better reimbursement for RhD NIPT via its PLA code, and a larger oncology share, since oncology carries a higher overall ASP than prenatal. Rising ASP is just part of the picture—ongoing improvement in COGS per test stays central to how we run the business. In Q3, cost of goods sold for each test averaged $169, up from $161 in the prior quarter. That reflects the ongoing shift in our mix toward oncology as well as certain temporary costs tied to recent product launches. Within oncology, COGS per test keeps getting better, and notably Northstar Response has already reached roughly break-even on gross margin. Since oncology is expanding more quickly than prenatal, we still expect overall COGS per test to rise gradually as time goes on. On gross margin, we posted 71% in the third quarter, about one percentage point above the same period a year earlier, helped by higher ASPs. Prenatal gross margin was 75%, and oncology gross margin climbed to 45%, which is before accounting for any Medicare coverage of Northstar Response. Even with oncology continuing to grow far more rapidly than prenatal, ASPs rising in both prenatal and oncology, and ongoing cost reductions in oncology, we've kept a superior gross margin profile. We think we can maintain this profile as oncology becomes a much bigger portion of our business; with that, I'll hand the call to Ross to go over our financial results and guidance before I wrap up.
Thank you, Ozan. As Ozan noted, the third quarter of 2026 delivered a strong performance for us, pairing 47% revenue growth year over year with a 9% GAAP operating profit margin and an 18% adjusted EBITDA margin. Total revenue for Q3 2026 came in at $123.0 million, up from $83.5 million in the third quarter of 2025. Both of our product lines, prenatal and oncology, showed strong growth during the quarter. Prenatal revenues — which include clinical testing revenues along with revenues from clinical trial support and other services — rose 42% to $105.9 million in Q3. Oncology revenues climbed 96% to $17.1 million in Q3 of 2026 versus the same quarter last year. Growth in our total revenue came mainly from test volume in both prenatal and oncology, together with continued year-over-year expansion of our prenatal ASP. True-up revenue totaled $7.6 million in the third quarter of 2026, versus $2.8 million in the second quarter of 2026 and $3.7 million in the third quarter of last year. If you exclude true-up revenue, total revenue was up 8% sequentially compared with the second quarter of 2026. True-up revenue increased on a sequential basis, primarily because of progress we made resolving the held claims issue with one payer that we talked about on our second quarter call. Gross profit for the third quarter of 2026 was $87.1 million, versus $58.4 million in the third quarter of 2025, which produced a gross margin of 70.9% in the third quarter of 2026 compared with 69.9% in the third quarter of 2025. The gross margin improvement was mainly due to continued increases in our overall ASP. Total operating expenses came to $76.1 million in the third quarter of 2026, compared with $48.8 million in the comparable prior-year quarter, an increase of 56%. Inside total operating expenses, R&D expense was $20.2 million in the third quarter of 2026, versus $13.0 million in the comparable prior-year quarter. SG&A expense was $55.9 million in the third quarter of 2026, versus $35.8 million in the comparable prior-year quarter. Operating income was $11.0 million in the third quarter of 2026, compared with operating income of $9.6 million in the third quarter of 2025. Our operating profit margin was 9%, versus the 5% operating margin we delivered in the second quarter of 2026. Net income available to common shareholders was $17.4 million, or $0.32 per diluted share in the third quarter of 2026, compared with net income of $1.5 million, or $0.10 per diluted share for the same period in 2025. Turning to the cash flow statement for the third quarter, cash flow from operations in Q3 was $12.5 million, while capital expenditures were $3.9 million. That gave us free cash flow of $8.6 million in the third quarter of 2026. We are well-capitalized, with a very healthy balance sheet. We finished the third quarter with $562 million in cash and equivalents. We believe our balance sheet positions us well for strong growth ahead. Finally, I will give an update on our full-year guidance for 2026. For 2026, we're lifting our total revenue guidance to a range of $460 million to $470 million, up from the earlier $450 million to $465 million. At the midpoint, that works out to an increase of $7.5 million, and it reflects growth of roughly 51% to 54% versus full-year 2025. On top of that, we intend to run the business so that it keeps producing profitability in line with where we are now, even as we make substantial ongoing investments. With that, I'll hand the call back to Ozan for closing remarks.
Thank you, Ross. In closing, our mission hasn't changed: we're transforming healthcare one molecule at a time and one patient at a time. What gives me confidence isn't any single result — it's how every part of our business reinforces the others. Each piece of evidence we publish makes the case for our platform stronger. This quarter, a prospective study validated UNITY Fetal Risk Screen as a first-line test, and our head-to-head data showed Northstar Response delivering performance on par to superior versus a tumor-informed assay. Every launch widens our platform's reach, and next month Northstar Clear will extend it into early-stage cancers with MRD. Our financial profile keeps setting us apart. Revenue grew 47% year-over-year, gross margins held at 71%, we delivered a 9% GAAP operating margin and an 18% adjusted EBITDA margin, and we raised our outlook for the year; we believe we're truly differentiated in molecular diagnostics, with our unique and proprietary technology positioning us for sustainable growth and long-term profitability. Our long-term goal is the same: to transform molecular diagnostics, build a category-defining company, and earn our place in the S&P 500. We're proud of what we've accomplished through the first three quarters of 2026, and we look forward to sharing our annual results with you on our next call. Thank you. Over to the operator.
Hello, Ricki here, filling in for Subu. We appreciate you taking our question. Perhaps to start, there were a few shifts lately on the competitive side in prenatal. With Labcorp now owning Foregent, which includes fetal recessive testing components, does that affect anything regarding your competitive positioning, or the way you're going about the market when it comes to competition?
Thanks for that question, Ricki. In the past, prior acquisitions and consolidations have caused disruption for customers and turned into growth opportunities; we think this could be another solid opportunity for us to drive further organic growth; we think our UNITY Fetal Risk Screen is so differentiated, with so much clinical data behind it, that other tests entering the market won't have a meaningful impact on where we stand competitively.
That's clear. So as a follow-up, on both prenatal and oncology, I suppose: have you noticed any lift in volumes yet from EMR ordering? And if not, when might that begin to show?
We're beginning to see impact from some of the earlier integrations, even in accounts already using us. With EMR, it's sometimes simpler to integrate accounts that may already be using our test in another form. In those accounts, we're seeing a higher number of tests, even where they were fully converted before; we're also pursuing new health system adoptions with a number of health systems; and we saw last year with Q2 and Q3 that each health system can add significant test volume growth. That's why we're putting so much investment into the health systems side, with Epic Aura and the UNITY Fetal Risk Screen expanding to 130 genes.
Thank you.
Hey guys. Thanks for taking the questions, and congratulations on a strong beat-and-raise quarter. I'd like to begin with Northstar Clear. I really do like the branding behind the test's name. When other companies in this space launch an MRD test that isn't reimbursed, we've seen them sort of manage volume growth in order to limit some of the drag on the bottom line. I just wanted to ask, maybe you could walk us through your plan? I know it launches on December 15th, but to what extent do you put this test in the hands of all of your reps? How hard do you push it? Would you be able to walk us through your reimbursement timelines and highlight any specific indications?
Thanks, Mark, for the question and the kind remarks. This is genuinely an area where we stand apart. Since the way we build assays and the degree to which QCTs boost the signal relative to other methods, we've engineered our MRD test to carry a far lower cost profile than several other MRD tests available on the market. Actually, our view is that rising test volume will bring it to where Response stands now — it will turn gross margin positive even without any Medicare coverage. The implication is that, unlike other firms that must cap test volume owing to bottom-line effects, we face no such need, since we do not anticipate any bottom-line hit as MRD scales. That is exactly why we will not restrict the indication. In my view, this can produce quicker growth in test volume than a narrower launch that competitors may be compelled to pursue.
That's great to hear. So I understand this is a pan-cancer assay. Typically, others have begun with colorectal before expanding into larger indications such as breast or lung. Could you give us some insight into how your reimbursement path is shaping up? I'm not sure whether you're able to speak to any indications where you intend to file data. I realize that's still months off, but how should we frame the cancer types you may go after at first?
As you noted, we're running studies in all three of the biggest cancer types — colorectal, lung, and breast — along with their subtypes. Naturally, MRD studies also require more time. What we'll launch with is head-to-head data on CRC plus some clinical data on CRC. We've been gathering samples to conduct clinical studies in multiple cancer types; our first submissions might also begin in CRC, though we think a tissue-free test offers meaningful advantages beyond CRC, particularly since tissue availability is far lower in other cancer types and tumor-informed tests show much higher QC fail rates.
Great. Perhaps one final quick question. I recall that when you went public, you mentioned welcoming direct competition. It's good to see the Northstar Response data compared with a different tumor-informed assay. I'm curious, Ozan, whether you intend to run additional head-to-head studies, be it with Northstar Select or with Northstar Clear; such studies require time, so I'm wondering if we might expect some perhaps in '27, or does that fall on a later timeline?
We've already published a peer-reviewed study against every competitor that existed at the time for Northstar Select, in which we demonstrated 51+% more actionable therapies. In clinics, we keep conducting those head-to-heads to demonstrate, for their own patients and for a practice, that we can identify substantially more options for patients. That is among the major drivers behind our growth. We are winning these head-to-heads literally every day in the clinics and in the field for Northstar Select. For Northstar Clear, at launch, as I said, we will actually run a head-to-head too against a tumor-informed competitor; that one is going to be in CRC initially. Down the road, I believe we can certainly explore additional head-to-heads for MRD as well; this is among the areas where I think we are genuinely differentiated from other molecular diagnostics companies. We truly welcome these head-to-heads as a way to show that our tests are superior.
That's excellent. I really appreciate you making the time.
Hey everyone, thanks for the questions. Ozan, regarding prenatal volumes, according to my calculations, the volume figure came out around 190,000 or thereabouts. Is that roughly right? And then I believe the seasonal pattern you typically see means 4Q is often comparable to 3Q; that would sort of place the prenatal volume growth figure in the mid-20s for the year. Looking ahead to next year, and I realize we'll get the specifics next quarter regarding next year, but you've got rep productivity, you've got UNITY Confirm, you've got progress on EMR integration, and then there's this new 130-gene panel. Again, I know the guidance will come at the start of 2027, but as a starting point, do you expect volume growth to speed up next year for prenatal?
I believe it comes down to timing regarding all these health system initiatives we're pursuing. Dan, we discussed this somewhat before, but just to remind everyone, prenatal isn't a monolithic market, correct? There are independent clinics, roughly 40% of the market, and then health systems make up about 60% of the market. Historically, our products, our positioning, our consistent quarter-over-quarter growth really centered on those single-specialty clinics. Naturally, it's far simpler to grow within that 40%, going from 5% to 10% and then 10% to 20%. As we become the largest market share holder in independent clinics, it's not surprising that growth in independent clinics would decelerate. Looking at health systems, though, that's still a very large untapped opportunity representing 60% of the total market; that's what we observed in Q2, Q3 last year when we had nearly 20,000 sequential growth in Q3 last year, which was, I believe, the strongest test volume quarter growth we've possibly ever achieved. That's really when we recognized the need to invest in health system growth; that's why we did the Epic Aura integration, we expanded to 130 gene. All of these things were necessary to keep winning health systems. Health systems involve long sales cycles; these are 12, 18, 24-month discussions. With some of them, I think we're getting nearer to the finish line, and we can definitely see upside to test volumes for prenatal as they happen. I also think we're going to see oncology contributing a bigger and bigger component of growth next year as well, coming probably closer in terms of sequential test volume growth similar to prenatal levels.
Then, just to follow up on that, Ross — the new revenue figure, the range for the year — does it bake in some amount for true-ups in 4Q?
No, Dan, we leave any true-up revenue out of our forward-looking guidance. The historical true-up is in there, but for Q4 we don't include anything. Got it.
Just double-checking. Appreciate it.
Hi everyone, Noah here covering for Tycho. Thanks for letting us ask questions. I'd like to begin with the new CLFS proposal. It appears your carrier screening rate is set to rise by 112%, and there's also an increase on Northstar Response, though I believe several of the aneuploidy codes will decline next year. So how are you viewing those moving parts, is there any effect on ASPs, and how does that carry over to other payers such as Medicaid and commercial plans?
Thanks for asking. Naturally, whether these preliminary changes will actually take effect remains uncertain. I believe we're in a very lucky spot in that we're facing an overall increase instead of a decrease. The sole code we use that's shared with other labs broadly for a major test is the aneuploidy code, and as you mentioned, that one is going down. Our gain on the single-gene NIPT, I believe, will offset that. Over the long run, it genuinely raises the potential for single-gene NIPT to serve as a massive ASP driver to a very high level, particularly if clinical practice shifts and single-gene NIPT keeps getting reimbursed more and more. Regarding oncology, naturally that would be a real net positive for us if our Response goes up nearly 30% from a CLFS standpoint. Once more, it's hard to speak to the complete effect of how that will alter our Response ASPs prior to implementation; it certainly would, if it were to be implemented, I believe it would make our Response gross margins especially favorable even absent Medicare coverage.
Understood, thank you. That helps; so one additional item regarding oncology, given the upcoming MRD launch, what's your thinking on how many new sales reps you'll need to hire, and will the current sales team also be selling the MRD test? I may have missed this earlier, but is there any updated expectation on MolDX timing for Northstar Response?
On your first question, regarding a separate sales force, the same team will be used. Specifically, we think the providers already using our Select and Response tests have already moved over from other competitors to us; they have faith in the technology, they have faith in what we can deliver, and they have observed head-to-head results. In my view, those will be the initial customers we can approach to get them to switch. We also think MRD will create opportunities for us in places where access may previously have been challenging. Regarding Medicare coverage for Response, we think—and you may have seen this, I believe, in other timelines concerning tissue-free versus tumor-informed tests—that MolDX appears to set a far, far higher bar for tissue-free tests. That's the reason we conducted the head-to-head study demonstrating we are on par with or superior to the tumor-informed tests; we think that piece of evidence substantially de-risks Medicare coverage for Response. That's why we think it's a question of really when rather than if. Although we continue to think it could occur by the year-end, the timing remains uncertain.
Understood. Many thanks.
Thank you for taking the questions, and congratulations on the quarter. I was hoping you might expand a bit on health system penetration and how the rollout could unfold in 2027. I realize you'd rather not say much about guidance and the outlook, but just qualitatively — you have a pipeline of systems; how long might that take, and what might it mean in terms of additional tests coming online? Thanks.
Without going into specific figures, we have over 20 health systems at various stages of the pipeline, and each one can run anywhere from 2,000 tests to 5,000 tests per quarter. Naturally, not every one of these systems will materialize within the next 12 months, but the progress we're seeing across many of them encourages us a great deal. Quite often, it isn't even the clinical sell at all. At many of these healthcare systems, the clinical decision team may have already decided they want to move to UNITY, yet the EMR integration alone, along with legal, phlebotomy, and logistics, can take anywhere from 6 to even more than 12 months. When we think about guidance — and we aren't providing any for 2027 yet — we typically don't factor any of these health systems into it. I believe we will increasingly see greater contribution from these health systems in 2027 and 2028.
All right, thanks Ozan. Turning to the prenatal menu — it's a bit like the battles that play out among competitors. I don't believe the market has an answer yet when it comes to the 130-gene panel. So how big an edge does this type of innovation on the menu and the tests give you? Is that really the heart of it, or do you see a commercial advantage that you're gaining or building toward, I suppose, as the company matures?
Sure. What we've come to understand is that winning within these health systems requires products that appeal to each and every stakeholder. Historically, I think our smaller-panel products met the needs of OB-GYNs, and our fetal antigen test met those of MFMs. Since we lacked even standalone carrier panels of larger size, not to mention single-gene NIPT, I don't believe we were addressing the complete needs of each and every stakeholder — genetic counselors included, for example. We came to see that each stakeholder matters within a health system, and everyone has to be enthusiastic for them to endure the hassle of switching; that's why I believe the 130-gene offering is such a significant addition. It may not be the assay that accounts for most of the test volume, but it turns into one that opens up these conversations in health systems.
When we launch, the clinical data will center on CRC, since I believe that's the area where we can demonstrate genuine apples-to-apples comparisons against other tumor-informed assays. In 2027, we will certainly have additional cancer types plus further data readouts, and we've already begun clinical studies for those. Appreciate that. As a follow-up, your MRD assay has been very well telegraphed since last year. I'm wondering how much pent-up demand might exist among current oncology accounts that have been awaiting your launch. Are there accounts simply waiting for December 15th so they can adopt Northstar Clear, or is the investor community perhaps more aware that this test is coming than the oncologists are? There is certainly some pent-up demand. We haven't really been pre-selling and discussing our MRD much with customers, yet in some cases we already see physicians using our Response test even beyond the late-stage indication it was designed for. That tells me there's unmet need among our physicians, and they are already sometimes using our Response test for MRD. I think that's a really strong indication we'll see adoption among our existing physicians for our MRD test. That's helpful. Thank you.
Hi everyone, thanks for taking my question. First, I'd like to ask about consolidation and acquisitions in the prenatal space. Does that alter how you think about opportunities for market shifts? One thing about genetic tests that are usually about a decade old is that you sometimes see a lack of discipline in contracting from some of the players. Do you think that perhaps with a more concentrated environment, you could see more discipline in contracting and maybe some better ASPs down the road, or perhaps, say, less negative pressure on ASPs going forward?
Regarding ASPs, I think we've been so disciplined, Dave, that we've only contracted when the contracts would be additive to us, and we don't see a significant change that this would bring to the market. When it comes to test volume shifts, though, as I mentioned a little bit earlier, these acquisitions don't really tie customers to the acquiring party in any way. Previous acquisitions and consolidations have created a lot of disruption for customers who might be used to one way of dealing with their customer service, their lab operations, their results, their billing policies. As those things cause disruptions, they become really important growth opportunities for us and for any other parties that might be in a position to take advantage of this. We believe this is another good opportunity for organic growth.
Understood. Great. So, Ozan, I realize you've stayed quite strict when it comes to profitability and margins and so forth, and that shows up in the P&L and so on. Looking ahead, you've got this Clear product, plus additional oncology offerings in the pipeline. How are you weighing spending against that 70% gross margin and against the EBITDA positivity you've achieved? If you chose to loosen the purse strings a bit, would it go toward sales or perhaps capex, or do you see it as potentially an entire spectrum of new products — say MCED or something along those lines that would be larger in scale?
Over both the near term and the longer term, our aim is to keep our GAAP profitability intact. Since we engineer the assays with cost efficiency in mind, I don't expect that scaling our oncology products will hurt our GAAP profitability. Overall gross margins certainly could be affected as oncology grows into a larger share of the business, but we're confident we can achieve rapid growth while still investing in expanding the sales force — which fuels growth in test volume — and in the clinical studies as well, correct? Over the long run, clinical studies push such higher ASPs via coverage that this is an area where, in my view, it's sensible to keep investing and to invest more in 2027.
Thanks.
Hi there, good afternoon, Ozan. We covered quite a bit of ground in this session, but I'd like to dig deeper into that head-to-head you mentioned, the one you published in October. Roughly a month has passed since then. It certainly sounds compelling. I'm wondering, for those who haven't yet adopted Response, has it proven persuasive enough that some new providers are willing to give you a try — or, if not, is there something else they're seeking from the wider product lineup, things like workflow, turnaround time and so forth, that you may still need to bring forward?
In my view, this clinical study has already had real impact for us, since it demonstrates — building on the earlier head-to-head against Select — that our platform is both strong and superior. I believe it will keep fueling growth in our Response test volume. Response volume was very strong in Q3, and we expect that momentum to carry into Q4 and into 2027.
Good to hear that. So I suppose, just to sharpen the point regarding the favorable Clear remarks made during this call, it sounds as though Clear could become a meaningful revenue contributor in 2027, rather than simply being a year focused on evidence generation and funnel building. Is that accurate?
Of course, ASPs won't be in the thousands of dollars for a test that lacks Medicare coverage at this point. We're going to scale it. I think a better way to frame this is that we're now launching a tissue-free test with the potential to be truly category-defining. Historically, no tissue-free test has demonstrated performance on par with tumor-informed tests; this marks the first time physicians need not choose between convenience and sensitivity. Given that failure rates in some cancer types can be so substantial, I think having an ultra-sensitive tissue-free test will be a really big part of our long-term growth. For 2027, I think the revenue contribution will be modest, but over the long term, this can be the biggest revenue contributor among all of our product lines.
All right, appreciate the updates.
Thanks. I want to express my gratitude to all of you for being here. As I said before, the aim we have is to create a company that defines its category, and this quarter was yet another excellent one in our 20-mile march toward that goal. We're eager to share with you our Q4 and annual results on the next call. Thank you.
Thanks. That brings the conference to a close. We appreciate everyone taking part. You can go ahead and disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete BillionToOne, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to BillionToOne, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.